Modeling COVID-19 epidemics in an Excel spreadsheet: Democratizing the access to first-hand accurate predictions of epidemic outbreaks

Mario Moisés Alvarez[1,2,*], Everardo González-González[1,2], and Grissel Trujillo-de Santiago[1,3]

1) *Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, Monterrey 64849, NL, México*
2) *Departamento de Bioingeniería, Escuela de Ingeniería y Ciencias, Tecnologico de Monterrey, Monterrey 64849, NL, México*
3) *Departamento de Ingeniería Mecatrónica y Eléctrica, Escuela de Ingeniería y Ciencias, Tecnologico de Monterrey, Monterrey 64849, NL, México*

(*) corresponding author: *mario.alvarez@tec.mx*

Abstract

We present a simple epidemiological model that is amenable to implementation in Excel spreadsheets and sufficiently accurate to reproduce observed data on the evolution of the COVID-19 pandemics in different regions (i.e., Italy, Spain, and New York City). We also show that the model can be adapted to closely follow the evolution of COVID-19 in any large city by simply adjusting two parameters related to (a) population density and (b) aggressiveness of the response from a society/government to epidemics. Moreover, we show that this simple epidemiological simulator can be used to assess the efficacy of the response of a government/society to an outbreak. We believe that the simplicity and accuracy of this model will greatly contribute to democratizing the availability of knowledge in societies regarding the extent of an epidemic event and the efficacy of a governmental response.

Keywords: *COVID-19, coronavirus, SARS-CoV2, mathematical modeling, epidemic, pandemic, Excel*

To be submitted to *Scientific Reports*

Introduction

A SARS-CoV2 (COVID-19) pandemic was declared by the World Health Organization in March 2020. More than 100,000 positive cases of COVID-19 infection had been declared worldwide at that point, mainly in China, Italy, Iran, Spain, and other European countries. By the third week of March 2020, the pandemic also had a strong presence in Las Americas, mainly in the USA [1], with the number of cases in Latin America and Brazil [2] starting to increase alarmingly. COVID-19, the first pandemic of this decade and the second in less than 15 years, has harshly taught us that viral diseases do not recognize boundaries; however, they truly do discriminate between aggressive and mediocre containment responses.

Indeed, three months have passed since the emergence of COVID-19, and we have been able to observe exemplary responses from some Asian countries (i.e., China [3], South Korea [4], Singapore [5], and Japan), some highly aggressive responses in Europe and America (i.e., Germany and USA), and several delayed or not so effective responses from other regions (i.e., Italy and Spain). At this point, some territories in Latin America are just experiencing the "lag phase" of the COVID-19 pandemic at home and do not appear to have yet implemented proper containment measures as rapidly as needed.

The gap between developed and developing countries may explain some of the differences in the scale of the responses that we are observing. Countries that are better equipped than others in terms of high-end scientific development, diagnostics technology, and health care infrastructure may respond more efficaciously to a pandemic scenario. However, other tools, such as mathematical modeling, are much more widely available and may be of extraordinary value when managing epidemic events such as the COVID-19 pandemic. To date, many papers have reported the use of mathematical models and simulators to evaluate the progression of COVID-19 in local or more global settings [4,6–8]. Predictions on the possible evolution of COVID-19 based on mathematical modeling could therefore represent important tools for designing and/or evaluating countermeasures [7,9–11].

However, mathematical modeling may (and probably should) become a much more available tool in the case of public health emergencies—one ideally widely available to practically any citizen in any of our societies. One decade ago, during the influenza pandemics, mathematical modeling of epidemic events was the realm of privileged

epidemiologists who had (a) a fast computer, (b) programing experience, and (c) and access to epidemiological data. Today, those three ingredients are now reduced to a convectional laptop, very basic differential equation-solving skills, and access to a website with reliable online statistical information on the epidemics.

The main purpose of this contribution is to demonstrate that a simple mathematical model, amenable to implementation in an Excel spreadsheet, can accurately predict the evolution of an epidemic event at a local level (i.e., in any major urban area). This may be extremely valuable for government officials who must predict, with high fidelity, the progression of an epidemic event to better design their action strategies. Moreover, the democratization of the modeling of complex epidemic events will empower citizens, enabling them to forecast, decide, and evaluate.

Results and Discussion

Rationale of the model formulation

Here, we construct a very simple epidemiological model for the propagation of COVID-19 in urban areas. The model is based on a set of differential equations. The first equation of the set (equation 1) states that the rate of accumulation of infected habitants in an urban area (assumed to be a closed system) is given by the sum of the number of new infections (positive contribution), the number of recovered patients (negative contribution), and the number of deaths (negative contribution). A second differential equation states that the rate of accumulation of the infected but asymptotic population is proportional to the population of infected and symptomatic subjects (equation 2). Two additional equations relate the number of deaths and recovered patients with the number of newly infected ones (equation 3 and 4). Finally, the rate of depletion of the pool of the population susceptible to infection is given by the sum of recovered patients, asymptomatic infected, and deaths (equation 5). Recent experimental evidence suggests that rhesus macaques that recovered from SARS-CoV-2 infection could not be reinfected [12]. However, at this point, the acquisition of full immunity to reinfection has not been proved in humans, although it is well documented for other coronavirus infections, such as SARS, and MERS [13,14]. The analysis of sera of one COVID-19 patient showed a peak production of specific IgGs against SARS-COV-2 by two weeks after the onset of symptoms [15]. Based on immunological information on

SARS and MERS epidemiology and the limited evidence on the nature of the host immune response to SARS-COV-2, we assume here that recovered patients become immune to reinfection.

$dX_s/dt = R_{Infected\text{-}s} - R_{Recovered} - R_{Death}$ Equation (1)

$dX_{as}/dt = R_{Infected\text{-}as} = (1/0.4) * R_{Infected\text{-}s}$ Equation (2)

$dD/dt = R_{Death} = 0.023 * R_{Infected\text{-}s}$ Equation (3)

$dR/dt = R_{Recovered} = 0.977 * R_{Infected\text{-}s}$ Equation (4)

$dP_s/dt = - R_{Infected\text{-}as} - R_{Recovered} - R_{Death}$ Equation (5)

This system is equivalent to:

$dX_s/dt = R_{Infected\text{-}s} - R_{Recovered} - R_{Death}$ Equation (1)

where:

$R_{Infected\text{-}as} = (1/0.4) * R_{Infected\text{-}s}$ Equation (2´)

$R_{Death} = 0.023 * R_{Infected\text{-}s}$ Equation (3´)

$R_{Recovered} = 0.977 * R_{Infected\text{-}s}$ Equation (4´)

$P_{s_n} = P_{s_n\text{-}1} - (X_{as} + R + D)$ Equation (5´)

In this system, all equations depend on $R_{Infected\text{-}s.}$ Here, we propose a simple formulation for the evaluation of $R_{Infected\text{-}s}$ at the onset of a local epidemic event.

$R_{Infected\text{-}s} = dI_s/dt = \mu_o I_s$ Equation (6)

where μ_o is the specific rate of infection of a population in a large and vastly uninfected urban area. We further propose that μ_o may be calculated from actual epidemiological data corresponding to the first exponential stage of COVID-19 local epidemics. We determined the appropriate ranges of values for μ_o by analyzing the following publicly available data from different websites that continuously monitor the progression of confirmed cases of COVID-19 for different nations.

- https://ourworldindata.org/coronavirus;
- https://elpais.com/sociedad/2020/03/16/actualidad/1584360628_538486.html).

This model correctly describes the evolution of the number of newly infected during the initial stage of the epidemic episode. For later times, the rate of new infections is corrected by a term that depends on the demographic density (Dd) of the region. Therefore:

$$R_{Infected\text{-}s} = dI_s/dt = \mu_o I_s (Dd/Dd_{ref}) \qquad \text{Equation (7)}$$

In equation (7), $Dd=P_s/A$, where A is the surface area of the region subject to analysis. In this formulation, Dd is the total number of inhabitants of the region who are susceptible to infection, while Dd_{ref} is a value of demographic density in a densely populated urban area that the model uses as a reference. In this work, the demographic density of the city of Madrid is used as Dd_{ref}. Furthermore, since Dd is a function that considers only the population susceptible to infection, a counter is needed to continuously update the number of recovered patients, asymptomatic patients, and deaths. Therefore, at each time step during the numerical integration, the susceptible population is updated by subtracting the number of number of recovered patients, asymptomatic patients, and deaths.

Defining an expression for $R_{Infected\text{-}s}$ enables stepwise numerical integration, for example by the Euler method. We have implemented this solution in a spreadsheet. To that aim, differential equations (1) and (7) should be converted into their corresponding equations of differences:

$$\Delta X_s = \{R_{Infected\text{-}s} - R_{Recovered} - R_{Death}\} \Delta t \qquad \text{Equation (8)}$$

$$\Delta I_s = \{\mu_o I_s (Dd/Dd_{ref}) \} \Delta t \qquad \text{Equation (9)}$$

For all the simulation results presented here, we set Δt=1h= 1/24 day. We have solved this differential set, step by step, updating the values of $R_{Infected\text{-}s}$, $R_{Recovered}$, R_{Death}, and P_s, according to equations (2´) to (5´). The ratio (Dd/Dd_{ref}) is also recalculated at each time step using the updated value of P_s from equation (5´).

Selection of relevant epidemiological parameters for COVID-19

The number of asymptomatic inhabitants was calculated under the assumption that only 28.5% of the infected population develops symptomatology. This assumption should be regarded as arbitrary, since no reliable information specific for the ration between symptomatic and asymptomatic COVID-19 patients is available at this point. Our assumption of the distribution between symptomatic and asymptomatic patients was inspired by the high number of asymptomatic infected subjects estimated for other pandemic events. For instance, in the context of pandemic influenza A/H1N1/2009, up to 20–40% of the population in urban areas (i.e., Monterrey, México, and Pittsburgh, USA) [16,17] exhibited specific antibodies regardless of experiencing symptoms.

In addition, the average time of sickness was set at 14 days in our simulations, within the range reported from 14 to 32 days [18], with a median time to recovery of 21 days [19]. Therefore, the number of patients recovered (R) is calculated as a fraction of 0.977 of those infected 14 days previously. Similarly, asymptomatic patients are only removed from the pool of susceptibles after full recovery. Note that, in the current version of our model, asymptomatic patients are not considered part of the population capable of transmitting COVID-19, despite recently reported evidence that suggests that asymptomatic subjects (or minimally symptomatic patients) may exhibit similar viral loads [20] to those of symptomatic patients and may be active transmitters of the disease [3,21]. The number of deceased patients was calculated as 0.023 of those infected 14 days before. This mortality percentage (case fatality rate) lies within the range reported in recent literature for COVID-19 [8,22–24]. The time lapse of 14 days between the onset of disease and death was statistically estimated by Linton et al. in a recent report [25].

The straightforward implementation of the model in Excel (Supplemental Excel File 1), using the set of parameters described before, allows the calculation of all populations (I_s, X_s, X_{as}, D, R, and P_s) every hour. Note that this model enables the description of the progressive exhaustion of the epidemic, as expected by the progressive depletion of the susceptible population. Next, we discuss criteria for selection of the values of μ_o based on the initial behavior of the COVID-19 Pandemic at different urban areas around the globe.

Estimation of specific epidemic rate values

Figure 1A shows the progression on the number of COVID-19 positive cases in different regions, namely Spain (mainly Madrid), Iran (mainly Tehran), and New York City. We have selected these three data sets to illustrate that the evolution of the epidemic has a local flavor that mainly depends on the number of initial infected persons, the demographic density, and the set of containment measures taken by government officials and society. Figure 1B shows the natural log of the cumulative number of infections over time for the same set of countries. This simple plotting strategy is highly useful for analyzing the local rate of progression of the pandemic. If the local epidemic progression is consistent with a simple first order exponential model where $dI/dt = \mu*I$, then the integral form of this equation renders the linear equation: $\ln I/I_o = \mu*t$.

During the exponential phase, a straight line should be observed, and the slope of that line denotes the specific rate (μ) of the epidemic spreading. Note that COVID-19 has exhibited a wide range of spreading rates in different countries (from ~0.3 to ~0.9 day^{-1}). Note also that μ is related to the doubling time (t_d), often reported in population and epidemiological studies, by the equation $t_d = \text{Ln } 2/\mu$. Therefore, ranges of doubling times between 0.75 and 2.45 days are observed just among these three regional cases. Different exponential stages, perfectly distinguishable by their exhibition of different slopes, may be observed within the same time series. For instance, the outbreak in New York City (Figure 1B; blue symbols) was first described by an extremely high slope ($\mu_o = 0.926$ day^{-1}). However, after a series of measures adopted in New York City by the federal, state, and local governments, the specific growth rate of the epidemics fell to $\mu = 0.308$ day^{-1}. The last point is extremely important, since two drastically different slopes can be observed before and after a package of adequate measures within the same territory. In addition, two localities that experienced similar initial specific epidemic rates may exhibit dramatically different evolutions as a function of the initial response of government and society (Figure 1C,D). For instance, while the COVID-19 epidemics in Italy and South Korea exhibited practically equal μ_o values, the Italian outbreak has maintained the same growth rate throughout 20 days, while South Korea has set an example by effectively and rapidly lowering the specific epidemic rate to nearly 0 in just two weeks.



Figure 1. Epidemiological data related to the onset of a COVID-19 pandemic in different regions. (A) Cumulative number of positive cases of COVID-19 infection in Spain (yellow circles), Iran (green squares), and New York City (blue triangles) during the first days after the outbreak. (B) Natural logarithm of the cumulative number of positive cases of COVID-19 infection in Spain (yellow circles), Iran (green squares), and New York City (blue triangles). (C) Cumulative number of positive cases of COVID-19 infection in Italy (blue squares) and South Korea (red circles). (D) Natural logarithm of the cumulative number of positive cases of COVID-19 infection in Italy (blue squares) and South Korea (red circles). Two clearly distinctive exponential stages are observed in the case of South Korean progression.

Validation and predictions

We have run different scenarios to validate the predictive capabilities of our epidemic model for COVID-19. Overall, the model is capable of closely reproducing the progression of reported cases for urban areas of more than 5×10^6 inhabitants (i.e., Iran, the city of Tehran in Iran, Spain, and New York City). We found that, adapting the model to a particular locality is straightforward and only requires (a) the calculation of the population and the surface area of the urban area, and (b) the selection of a t_d value (time to doubling the name of infections). Note that our model is formulated in terms of values of the specific epidemic growth rate (μ_o for the onset of the epidemic and μ for later times). However, expressing the specific epidemic rate in terms of doubling time (t_d=Ln 2/μ) is more practical and simpler to communicate and understand.

The selection of μ_o (t_d) can be easily done by fitting the prediction to the initial set of reported cases of infection. In our experience, four to five reliable data points are needed for a good fit. For instance, Figure 2 shows the predicted trend of the pandemic in New York City during the first 22 days of March, 2020. In addition, we set (Dd/Dd_{ref}=1.90), since the population density in New York City is 1.90-fold higher than that in Madrid. A value of t_d= 2.25 was also set for the first week of this simulation. Later, at day 7 (March 7), we reset the value of t_d to 3.75 to reflect the modification of the slope of the local epidemic event in New York (Figure 1d), due to the implemented measures of containment. Based on this exercise, we foresee that this simple modeling tool can be used to evaluate the efficacy of containment strategies. In other words, the value of μ_o required in the simulation to adapt the predicted data to the actual trend of the local epidemic provides an indicator of the local rate of spreading of the pandemic. Therefore, the differences between μ_o before and after interventions provide a real-time quantitative measure of the effectiveness of that set of measures. This can be extremely useful when assessing the efficacy of control of epidemics. For example, for New York City, this simple model states that the set of containment measures adopted during the first week of March in NY City diminished the specific rate of the epidemic by increasing the doubling time of infections from a value of 2.25 to 3.75 days.



Figure 2. Progression of the COVID-19 Pandemic in New York City. (A) Initial evolution of the number of positive cases of COVID-19 in New York City. Actual data points, as officially reported, are shown using red circles. Simulation predictions are described by the blue dotted line. (B) Model prediction of new cases of COVID-19 during the period from March 1 to May 20, 2020 if no further containment actions are adopted. (C) Model prediction of the total number of symptomatic patients through the months of March and April.



Figure 3. Progression of the COVID-19 pandemic in the metropolitan area of Monterrey, Nuevo León, Mexico. (A) Initial evolution of the number of positive cases of COVID-19 in the metropolitan area of Monterrey. Actual data points, as officially reported, are shown using red circles. Simulation predictions are described by the blue dotted line. (B) Model prediction of new cases of COVID-19 during the period from March 1 to May 20, 2020 if no further containment actions are adopted. (C) Model prediction of the total number of symptomatic patients from March 1 to May 20, 2020.

The ability to make close predictions of the progression of cases in a particular region has profound and enabling implications. For example, our simulations predict that, in absence of more aggressive containment measures, the peak of infections in New York City will be reached by April 10, 2010 (twenty days after the submission of this manuscript), after reaching the unprecedented value of 11,000 new cases per day, and a cumulative number of 1×10^6 citizens infected.

We are currently following the onset of the COVID-19 pandemic in Monterrey, the second most industrialized city in México and the third most populated. Monterrey has a similar demographic density to that of Madrid (Dd/Dd_{ref}=0.95). In addition, we set t_d = 2.5, based on proper fitting to the first set of official values of COVID-19 infected announced for Monterrey by the local authorities from March 15 to March 18, 2020. Remarkably, the simulation results have accurately predicted the three subsequent actual values, as officially reported from March 19 to March 21.

Concluding remarks

We used a set of differential equations, recent epidemiological data regarding the evolution of COVID-19 infection in a reduced set of regions (i.e., Spain, Iran, and New York City), and basic information on the characteristics of COVID-19 infection (i.e., time from infection to recovery, case mortality rate) to accurately recreate the onset of the COVID-19 in two urban areas with different demographic characteristics (i.e., New York City and Monterrey, México). We showed that the model can be adapted to closely follow the evolution of COVID-19 in densely populated urban areas by simply adjusting two parameters related to (a) population density and (b) aggressiveness of the response from a society/government to epidemics.

Scenarios such as those currently unfolding in Iran, Italy, or Spain emphasize the importance of planning ahead during epidemic events. The availability of a simple model may be highly enabling for local governments, physicians, civil organizations, and citizens as they struggle in their endeavor to accurately forecast the progression of an epidemic and formulate a plan of action. As previously stated, the use of simple/user-friendly models to evaluate in (practically) real time the effectiveness of containment strategies or programs may be highly a powerful tool for analyzing and facing epidemic events [11]. This

contribution shows the prediction potential of an extremely simple simulation tool that can be used by practically any citizen with basic training in Excel. For instance, using this simple model, virtually any student could assess, in real time, the efficacy of the actions of her/his society in the face of an outbreak.

Acknowledgments

MMA, EGG, and GTdS acknowledge the funding received from CONACyT (Consejo Nacional de Ciencia y Tecnología, México).

References:

1. Holshue, M. L. *et al.* First Case of 2019 Novel Coronavirus in the United States. *N. Engl. J. Med.* (2020). doi:10.1056/nejmoa2001191
2. (No Title). Available at: https://www.researchgate.net/profile/Alfonso_Rodriguez-Morales/publication/339596618_COVID-19_in_Latin_America_The_implications_of_the_first_confirmed_case_in_Brazil/links/5e5aca5b92851cefa1d1e52b/COVID-19-in-Latin-America-The-implications-of-the-first-confirmed-case-in-Brazil.pdf. (Accessed: 22nd March 2020)
3. MacIntyre, C. R. Global spread of COVID-19 and pandemic potential. *Glob. Biosecurity* **1**, (2020).
4. Choi, S. C. & Ki, M. Estimating the reproductive number and the outbreak size of Novel Coronavirus disease (COVID-19) using mathematical model in Republic of Korea. *Epidemiol. Health* e2020011 (2020). doi:10.4178/epih.e2020011
5. Wong, J. E. L., Leo, Y. S. & Tan, C. C. COVID-19 in Singapore-Current Experience: Critical Global Issues That Require Attention and Action. *JAMA* (2020). doi:10.1001/jama.2020.2467
6. Peng, L., Yang, W., Zhang, D., Zhuge, C. & Hong, L. Epidemic analysis of COVID-19 in China by dynamical modeling. (2020).
7. Kucharski, A. J. *et al.* Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *Lancet Infect. Dis.* (2020). doi:10.1016/S1473-3099(20)30144-4

8. Jung, S. *et al.* Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases. *J. Clin. Med.* **9**, 523 (2020).
9. Hellewell, J. *et al.* Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. *Lancet Glob. Heal.* **8**, e488–e496 (2020).
10. Gostic, K., Gomez, A. C. R., Mummah, R. O., Kucharski, A. J. & Lloyd-Smith, J. O. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. *Elife* **9**, (2020).
11. Cauchemez, S., Hoze, N., Cousien, A., Nikolay, B. & ten bosch, Q. How Modelling Can Enhance the Analysis of Imperfect Epidemic Data. *Trends in Parasitology* **35**, 369–379 (2019).
12. Bao, L. *et al.* Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv* 2020.03.13.990226 (2020). doi:10.1101/2020.03.13.990226
13. Prompetchara, E., Ketloy, C. & Palaga, T. Allergy and Immunology Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. doi:10.12932/AP-200220-0772
14. Liu, W. *et al.* Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome. *J. Infect. Dis.* **193**, 792–795 (2006).
15. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
16. Elizondo-Montemayor, L. *et al.* Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method. *Int. J. Infect. Dis.* **15**, e781–e786 (2011).
17. Zimmer, S. M. *et al.* Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA. doi:10.1371/journal.pone.0011601
18. Lan, L. *et al.* Positive RT-PCR Test Results in Patients Recovered From COVID-19. *JAMA* (2020). doi:10.1001/jama.2020.2783
19. Bi, Q. *et al.* Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. *medRxiv* 2020.03.03.20028423 (2020). doi:10.1101/2020.03.03.20028423
20. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected

Patients. *N. Engl. J. Med.* **382**, 1177–1179 (2020).

21. Bai, Y. *et al.* Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA* (2020). doi:10.1001/jama.2020.2565

22. Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J. & Hsueh, P. R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents* **55**, 105924 (2020).

23. Xu, Z. *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* **0**, (2020).

24. Porcheddu, R., Serra, C., Kelvin, D., Kelvin, N. & Rubino, S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. *J. Infect. Dev. Ctries.* **14**, 125–128 (2020).

25. Linton, N. M. *et al.* Epidemiological characteristics of novel coronavirus infection: A statistical analysis of publicly available case data. doi:10.1101/2020.01.26.20018754